You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
堃博醫療-B(02216.HK):完成肺部去神經射頻消融系統首例註冊臨牀試驗
格隆匯 07-10 07:41

格隆匯7月10日丨堃博醫療-B(02216.HK)發佈公吿,公司已經完成其肺部去神經(TargetedLungDenervation簡稱“TLD”)射頻消融系統首例註冊臨牀試驗。“經支氣管鏡下靶向肺部去神經消融術治療慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease,COPD)(“COPD”)”的多中心臨牀隨機對照研究由四川大學華西醫院羅鳳鳴教授牽頭,計劃在全國26家中心開展,將對公司的肺部去神經射頻消融系統在治療COPD的安全性和有效性進行探究。該系統將為全球COPD患者帶來喜訊。是次手術由四川大學華西醫院呼吸與危重症醫學科劉丹教授團隊完成。

根據披露,COPD是一種常見的慢性呼吸疾病。根據弗若斯特沙利文報吿,2020年全球COPD病人數達到2.192億例。依據現有流行病學調查證據顯示,40歲以上的成人中COPD患病率為13.7%左右,但部分患者對藥物治療獲益十分有限。

靶向肺部去神經術治療COPD是一項國際領先的新興技術,主要是在支氣管迷走神經富集的區域通過靶向深層組織射頻消融來實現去神經,從而減輕整個肺部的氣道阻塞,達到治療COPD的作用。該項治療技術於2022年11月15日已被正式納入2023年版慢性阻塞性肺疾病全球倡議(Global Initiative for Chronic Obstructive Lung Disease,GOLD)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account